Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
Vertex Pharmaceuticals executive Mark E. Bunnage, EVP and Chief Scientific Officer, reported two transactions in Vertex common stock. On February 11, 2026, he made an open-market sale of 2,021 shares at $460.43 per share. On February 10, 2026, 1,127 shares were disposed of at $468.41 per share to cover tax obligations. After these transactions, he directly owns 12,914 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 26, 2025, indicating the trades were pre-scheduled rather than discretionary.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported a tax-related share disposition. On 02/10/2026, 2,145 shares of Vertex common stock were disposed of at $468.41 per share in a transaction coded "F," which indicates shares were used to satisfy a tax liability. After this transaction, Bozic directly owned 41,857 shares of Vertex common stock.
Vertex Pharmaceuticals executive Jonathan Biller reported share sales and tax-related share dispositions. On 02/11/2026, he sold 1,925 shares of Vertex common stock in an open-market transaction at $460.43 per share under a company-approved Rule 10b5-1 trading plan.
On 02/10/2026, 1,630 shares were disposed of at $468.41 per share to satisfy tax obligations by delivering shares. Following these transactions, Biller directly owned 20,819 shares of Vertex common stock.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer, reported two stock transactions in February 2026. On February 10, 2026, he disposed of 872 shares of common stock to cover tax obligations at a price of $468.41 per share. On February 11, 2026, he executed an open-market sale of 1,751 shares of common stock at $460.43 per share, made under a company-approved Rule 10b5-1 trading plan entered into on August 11, 2025. After these transactions, he directly owned 22,046 shares of Vertex common stock.
Vertex Pharmaceuticals executive Kristen Ambrose reported insider share sales and tax-related share withholding. On February 11, 2026, she completed an open-market sale of 1,376 shares of common stock at $460.43 per share. On February 10, 2026, 592 shares were disposed of at $468.41 per share to cover tax or exercise-related obligations.
Following these transactions, Ambrose directly owned 10,127 shares of Vertex common stock. The sales were made under a company-approved Rule 10b5-1 trading plan that was entered into on August 8, 2025, indicating the trades were pre-arranged rather than discretionary decisions at the time of sale.
Vertex Pharmaceuticals reported strong growth for 2025, with total revenue of $12.0 billion, up 9% from 2024, and fourth quarter revenue of $3.19 billion, up 10%. Growth was driven by cystic fibrosis (CF) therapies and new products ALYFTREK, CASGEVY and JOURNAVX.
GAAP net income for 2025 was $3.95 billion, compared to a GAAP net loss of $(535.6) million in 2024, which was impacted by acquisition-related R&D. Non-GAAP net income rose to $4.75 billion from $110.6 million. Cash, cash equivalents and marketable securities reached $12.3 billion at year-end.
For 2026, the company guides to total revenue of $12.95–$13.1 billion, including $0.5 billion or more from non-CF products, and plans continued heavy investment in R&D and SG&A while advancing a broad mid- and late-stage pipeline across CF, gene editing, kidney disease, pain, autoimmune and diabetes programs.
Capital Research Global Investors filed a Schedule 13G/A reporting beneficial ownership of 17,319,044 shares of Vertex Pharmaceuticals Inc. common stock, representing 6.8% of the 253,718,831 shares believed to be outstanding as of the event date.
The filer reports sole voting power over 17,303,696 shares and sole dispositive power over 17,319,044 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Vertex.
A shareholder has filed a notice of proposed sales of common stock, indicating an intent to sell 1,925 shares through Fidelity Brokerage Services LLC on or around 02/11/2026 on the NASDAQ. The filing lists an aggregate market value of $886,327.75 for these shares and shows 253,718,831 shares of this class outstanding.
The 1,925 shares were acquired on 02/10/2026 through restricted stock vesting from the issuer as compensation. The document also reports that Jonathan Biller sold 347 common shares for $155,803.00 on 12/03/2025 during the past three months.
Edward Atkinson, a holder of Vertex Pharmaceuticals (VRTX) common stock, has filed a notice of proposed sale of 1,751 common shares through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $806,212.93.
The 1,751 common shares were acquired on 02/10/2026 via restricted stock vesting from the issuer as compensation. The notice also reports that Atkinson sold 2,500 common shares on 11/17/2025 for gross proceeds of $1,086,450.00. Vertex had 253,718,831 common shares outstanding at the time referenced.
A holder of Vertex Pharmaceuticals (VRTX) filed a Rule 144 notice to sell 2,021 common shares through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 02/11/2026. The filing lists an aggregate market value of $930,529.03 and 253,718,831 shares outstanding.
The 2,021 shares derive from restricted stock vesting on 02/10/2026, received as compensation from the issuer. The filing also notes a prior sale by Mark E. Bunnage of 23 common shares on 12/29/2025 for gross proceeds of $10,649.00.